TABLE 2.
Clinical characteristics, serotypes, PFGE profiles, and STs of other PNSP isolates
| STa | Allelic profilea,b | Serotype | Other countries of isolation | PFGE type | No. of isolates | Site(s) of isolationc,d | Yr of isolation | pbp profilee | MIC (μg/ml)f
|
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PEN | AMX | CXM | CRO | FEP | MEM | |||||||||
| 490 | 2-13-9-1-6-19-14 | 6A | Bulgaria, Finland, Greece, Greenland, Sweden | 15 | 1 | Sputum | 2002 | WT-13-7 | 0.12 | 0.12 | 0.25 | 0.12 | 0.25 | 0.12 |
| 490 | 2-13-9-1-6-19-14 | 6B | 16 | 1 | BAL | 2002 | 5-1-3 | 1 | 0.5 | 2 | 0.5 | 0.5 | 0.25 | |
| 1049 | 2-25-9-1-6-19-14 | 6A | 15 | 1 | BAL | 2001 | WT-13-8 | 0.12 | 0.06 | 0.25 | 0.25 | 0.25 | 0.12 | |
| 1019 | 7-8-1-10-15-14-14 | 6A | 17 | 1 | Eye | 1997 | 5-14-WT | 0.5 | 0.5 | 2 | 0.12 | 0.5 | 0.06 | |
| 135 | 7-5-4-12-6-20-46 | 6B | Germany, Spain | 18, 19 | 2 | Eye, blood | 2002 | 5-15-WT | 0.25 | 0.12 | 0.25 | 0.25 | 0.25 | 0.06 |
| 1010 | 1-5-29-10-6-79-18 | 11A | 20 | 1 | Sputum | 1999 | NT-16-WT | 0.25 | 0.12 | 0.5 | 0.25 | 0.25 | 0.06 | |
| 143 | 7-5-10-18-6-8-1 | 14 | Hungary, Portugal | 4f, j, k, m, n, o, p, r, s, t, 6 | 14 | BAL, blood, CSF, pleural fluid, sputum | 1995-1996, 1999-2002 | 1-1-1 | 2 | 1-2 | 4-16 | 1-2 | 1-2 | 0.5 |
| 143 | 7-5-10-18-6-8-1 | 14 | 4l | 1 | BAL, sputum | 2001 | 1-6-1 | 2 | 1 | 8 | 1 | 1 | 0.5 | |
| 143 | 7-5-10-18-6-8-1 | 14 | 4f | 1 | Blood | 2002 | 1-11-1 | 2 | 0.25 | 4 | 1 | 0.5 | 0.5 | |
| 143 | 7-5-10-18-6-8-1 | 14 | 4j | 1 | CSF | 2002 | 1-17-1 | 2 | 2 | 16 | 2 | 1 | 0.5 | |
| 790 | 7-5-10-18-6-58-1 | 14 | Portugal | 4k | 1 | CSF | 1999 | 1-1-1 | 2 | 1 | 8 | 1 | 1 | 0.5 |
| 1477 | 7-5-10-18-6-145-1 | 14 | 4l | 1 | BAL | 2002 | 1-1-1 | 2 | 1 | 4 | 1 | 1 | 0.5 | |
| 1625 | 1-19-2-17-1-28-168 | 19A | 21 | 2 | BAL, sputum | 2001 | 8-WT-WT | 0.5 | 0.25 | 0.12 | 0.12 | 0.12 | 0.12 | |
| 1027 | 10-41-47-1-6-14-2 | 19F | 23 | 1 | Sputum | 1999 | 5-18-9 | 0.5 | 0.03 | 0.12 | 0.03 | 0.12 | 0.06 | |
| 277 | 7-13-8-6-6-12-8 | 23F | Iceland, The Netherlands | 24 | 1 | Sputum | 1999 | 9-18-11 | 0.5 | ≤0.03 | 0.25 | 0.06 | ≤0.03 | ≤0.03 |
| 230 | 12-19-2-17-6-22-14 | 24F | Italy, Portugal | 22d | 1 | Blood | 1998 | NT-19-WT | 0.5 | 0.06 | 0.5 | 0.12 | 0.12 | 0.06 |
| 276 | 2-19-2-17-6-22-14 | 19A | The Netherlands, Portugal | 22b | 1 | Sinus | 2001 | 8-1-WT | 1 | 0.5 | 4 | 1 | 0.5 | 0.25 |
| 276 | 2-19-2-17-6-22-14 | 19A | 22c | 1 | Sputum | 2002 | NT-1-WT | 1 | 0.5 | 4 | 1 | 1 | 0.25 | |
| 319 | 12-19-2-17-6-22-9 | 19A | 22a | 1 | Sinus | 1999 | NT-19-10 | 1 | 0.06 | 0.5 | 0.12 | 0.25 | 0.12 | |
| 317 | 2-10-50-29-6-19-59 | Rough | 25, 27 | 2 | Eye, BAL | 1995, 2001 | NT-20-WT | 0.5 | 0.5 | 0.5 | 0.12 | 0.5 | 0.06 | |
| 1473 | 2-10-50-29-6-19-160 | Rough | 26 | 1 | Sinus | 1996 | NT-21-WT | 0.5 | 0.06 | 0.5 | 0.12 | 0.25 | 0.06 | |
a
New STs and alleles are underlined.
b
In the order aroE-gdh-gki-recP-spi-xpt-ddl.
c
BAL, bronchoalveolar lavage; CSF, cerebrospinal fluid.
d
Susceptibilities, serotypes, and STs of meningitis-related isolates were described in reference 39, and ciprofloxacin-nonsusceptible isolates (single isolates of ST81, ST276, and ST1477 and two isolates of ST156) were described in reference 38.
e
In the order pbp1a-pbp2x-pbp2b. NT, nontypeable; other, pattern unique to an ATCC clone.
f
PEN, penicillin; AMX, amoxicillin; CXM, cefuroxime; CRO, ceftriaxone; FEP, cefepime; MEM, meropenem.